Aura Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $596.69M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | $-0.50 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.40 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | – | $-0.47 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | $-0.55 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | After market close | – | $-0.42 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 11, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| restructuring charges | third quarter of 2026 | $2.90M to $3.20M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Aura Biosciences filed with the SEC
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Results of operations · Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Exit or restructuring costs · Executive or director change · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Innovating the future of cancer care to cure patients and preserve organ function May 2026 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Innovating the future of cancer care to cure patients and preserve organ function March 2026 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Innovating the future of cancer care to cure patients and preserve organ function November 2025 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Innovating the future of cancer care to cure patients and preserve organ function August 2025 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
patients and preserve organ function
Material agreement · Other events · EX-99.1 to Form 8-K
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Innovating the future of cancer care to cure patients and preserve organ function March 2025 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Innovating the future of cancer care to cure patients and preserve organ function November 2024 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
preserve organ function October 17, 2024 1
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
patients and preserve organ function
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Corporate Presentation August 2024 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Material agreement · Results of operations · EX-99.1 to Form 8-K
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Results of operations · Other events · EX-99.1 to Form 8-K
Corporate Presentation August 2023 Exhibit 99.2
Results of operations · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Results of operations · Other events · EX-99 to Form 8-K
Corporate Presentation May 2023 Exhibit 99.2
Results of operations · Other events · EX-99#2 to Form 8-K
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
Results of operations · EX-99 to Form 8-K
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
include statements about the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
Results of operations · Other events · EX-99.1 to Form 8-K